Poster presented at 9th international Symposium in Avian Influenza – Athens, GA, USA – April 12-15, 2015.
• View the Poster as a PDF file
CEVA has developed an effective genetically engineered vector vaccine against H5 avian influenza. The product is used commercially in North Africa. Although current Federal policy disallows vaccination, if eradication proves infeasible in the face of extensive spread, the CEVA product will prove valuable in a program to suppress clinical infection.